中国医院用药评价与分析Issue(7)：941-943,944,4.DOI:10.14009/j.issn.1672-2124.2015.07.040
沙格列汀联合二甲双胍治疗2型糖尿病的系统评价
Efficacy and Safety of Saxagliptin plus Metformin for Type 2 Diabetes Mellitus:A Systematic Review
魏玲玲 1林令华 1冯亮2
作者信息
- 1. 东海县人民医院药剂科，江苏连云港 222300
- 2. 东海县药品检验所药理室，江苏连云港 222300
- 折叠
摘要
Abstract
OBJECTIVE:To evaluate the efficacy and safety of saxagliptin plus metformin for type 2 diabetes mellitus.METHODS:The databases including Cochrane Library, PubMed and EMbase were searched to collect the randomized controlled trials ( RCTs ) on saxagliptin plus metformin in the treatment of type 2 diabetes mellitus in accordance with the exclusion and inclusion criteria.Meanwhile, the references of the included studies were also retrieved.Two reviewers independently assessed the quality of the RCTs, collected and cross-checked the data.All data were analysed statistically using Review Manager 5.2 software. RESULTS: Five studies involving 2 156 participants were included.Te results of meta-analysis showed that saxagliptin plus metformin group was better than in metformin group in terms of improvement of HbA1c levels(WMD=-0.47, 95%CI=-0.68--0.14, P<0.05)and in FPG levels ( WMD =-15.52, 95%CI =-19.85--11.19, P <0.05 ) .However, there was no statistically significant diference between the two groups in hypoglycemia events(RR=1.15, 95%CI=0.75-1.76, P=0.52). CONCLUSIONS:Saxagliptin plus metformin is safe and effective in treatment of type 2 diabetes mellitus, which is better than metformin alone in reducing HbA1 c level and FBG ( fasting blood glucose ) level; however, there is no statistically significant diference between the two groups in hypoglycemia events.关键词
沙格列汀/二甲双胍/2型糖尿病/Meta分析/系统评价Key words
Saxagliptin/Metformin/Type 2 diabetes mellitus/Meta-analysis/Systematic review分类
医药卫生引用本文复制引用
魏玲玲,林令华,冯亮..沙格列汀联合二甲双胍治疗2型糖尿病的系统评价[J].中国医院用药评价与分析,2015,(7):941-943,944,4.
